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http://dx.doi.org/10.1016/j.jaci.2016.02.001patients and patients with COPD and explore their relationship
with airflow limitation.
Methods: Asthmatic patients (n 5 171), patients with COPD
(n 5 81), and healthy subjects (n 5 49) recruited from a single
center underwent QCT and clinical characterization.
Results: Proximal airway percentage wall area (%WA) was
significantly increased in asthmatic patients (62.5% [SD, 2.2])
and patients with COPD (62.7% [SD, 2.3]) compared with that
in healthy control subjects (60.3% [SD, 2.2], P < .001). Air
trapping measured based on mean lung density expiratory/
inspiratory ratio was significantly increased in patients with
COPD (mean, 0.922 [SD, 0.037]) and asthmatic patients (mean,
0.852 [SD, 0.061]) compared with that in healthy subjects (mean,
0.816 [SD, 0.066], P < .001). Emphysema assessed based on lung
density measured by using Hounsfield units below which 15% of
the voxels lie (Perc15) was a feature of COPD only (patients
with COPD: mean, 2964 [SD, 19.62] vs asthmatic patients:
mean, 2937 [SD, 22.7] and healthy subjects: mean, 2937 [SD,
17.1], P < .001). Multiple regression analyses showed that the
strongest predictor of lung function impairment in asthmatic
patients was %WA, whereas in the COPD and asthma
subgrouped with postbronchodilator FEV1 percent predicted
value of less than 80%, it was air trapping. Factor analysis of
QCT parameters in asthmatic patients and patients with COPD
combined determined 3 components, with %WA, air trapping,
and Perc15 values being the highest loading factors. Cluster
analysis identified 3 clusters with mild, moderate, or severe lung
function impairment with corresponding decreased lung density
(Perc15 values) and increased air trapping.
Conclusions: In asthmatic patients and patients with COPD, lung
function impairment is strongly associatedwith air trapping,with
a contribution from proximal airway narrowing in asthmatic
patients. (J Allergy Clin Immunol 2016;137:1413-22.)
Key words: Asthma, chronic obstructive pulmonary disease, airway
remodeling, quantitative computed tomography, asthma-COPD
overlap syndrome, small airway disease, emphysema, gas trapping
Asthma and chronic obstructive pulmonary disease (COPD)
cause considerable morbidity and consume substantial health care
resources.1,2 Both airway diseases are characterized by airflow
obstruction, which is typically variable and reversible in asth-
matic patients but fixed in patients with COPD.3 However, there1413
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with severe asthma and those with COPD, because severe asthma
can be characterized by persistent airflow obstruction and some
patients with COPD have partially reversible airflow obstruction.
Similarly, there is emerging evidence of overlap between asthma
and COPD in terms of inflammatory profiles, with the former
typically associated with eosinophilic and the latter with
neutrophilic inflammation, but both patterns were observed in
subgroups of each disease.3-5
Quantitative computed tomography (QCT) has become an
established technique for airway morphometry and lung densi-
tometry in patients with airway disease.6-8 This approach allows
for quantification of proximal airway remodeling by means of
assessment of airway lumen and wall geometry, air trapping as
an indirect measure of small-airway disease, and emphysema
determined by means of lung densitometry. QCT has been applied
extensively to patients with COPD. Indeed, a systematic review in
2012 found that bothmarkers of emphysema and peripheral airway
measurements correlated with airflow obstruction in patients with
COPD.9 QCT in patients with COPD is generally accepted as a
robust method, especially for quantifying emphysema.10
QCT-measured emphysema has been shown to predict mortality11
and has been linked to lung function decrease.12 QCT in asthmatic
patients has demonstrated tremendous heterogeneity in airway
remodeling, showing that change in lumen dimension is an
important aspect of proximal airway remodeling8 and identifying
that changes in airway geometry are associated with histologic
features of airway remodeling.13-15 Whether the relationships
between lung function and QCT parameters are different in
asthmatic patients and patients with COPD is uncertain.
Our hypotheses were as follows: (1) QCT morphometric and
densitometric measures of proximal airway remodeling, air
trapping, and emphysema are different between asthmatic
patients, patients with COPD, and healthy subjects, and (2) in
asthmatic patients and patients with COPD, the association
between lung function impairment (postbronchodilator FEV1
percent predicted) and these QCT morphometric and densito-
metric measures are distinct. The coprimary QCT outcome
variables were as follows: mean airway lumen area (LA)/body
surface area (BSA) and percentagewall area (%WA) for proximal
airway remodeling; mean lung density expiratory/inspiratory
ratio (MLDE/I) for air trapping; and Hounsfield units below which
15% of the voxels lie (Perc15) for emphysema.
To test our hypotheses, we undertook a QCT observational
study of asthmatic patients and patients with COPD across the
spectrum of disease severity and investigated the relationshipbetween lung function and QCT parameters first in each disease
and second in QCT-derived clusters of the disease groups
combined. Some of the results of this study have been previously
reported in the form of an abstract.16,17
METHODS
Subjects
Adults with COPD (n 5 81) or asthma (n 5 171) and healthy control
subjects (n 5 49) were recruited at a single center, Glenfield Hospital,
Leicester, United Kingdom. Patients with COPD and asthmatic patients were
recruited from respiratory outpatient clinics, and healthy control subjects
were recruited through posters and advertisements placed in public areas,
including outpatient clinics in the hospital, support groupmeetings, and leisure
centers. Patients with COPDand asthmatic patients fulfilled diagnostic criteria
per Global Initiative for Chronic Obstructive Lung Disease and Global
Initiative for Asthma guidelines, respectively.18,19 Patients with COPD had a
greater than 10 pack year smoking history and were more than 40 years old.
Twenty-nine healthy control subjects and 60 asthmatic patients participated
in previous studies.7,8 The study was approved by the Leicestershire Ethics
Committee, and patients provided written informed consent.
It was ensured that all subjects with airway disease at the time of study
visits were free from an exacerbation requiring systemic corticosteroids,
antibiotics, or both for at least 6 weeks. All subjects underwent extensive
clinical characterization, including thoracic computed tomography (CT), lung
function tests, spirometry, full blood count, sputum analysis, and health status
questionnaires. The St Georges Respiratory Questionnaire for patients with
COPD and the Asthma Quality of Life Questionnaire and Asthma Control
Questionnaire for asthmatic patients were used.
CT
Volumetricwhole lung scanswere obtained by using a Siemens Sensation 16
scanner at a single center at full inspiration (near total lung capacity) and at the
end of expiration (near functional residual capacity). Details of CTacquisition
and quantitative airwaymorphometry and lung densitometry are provided in the
Methods section in this article’s Online Repository at www.jacionline.org. All
scans were analyzed by a single observer (RH) using the semiautomated
software Apollo (VIDA Diagnostics, Coralville, Iowa), and various QCT
parameters were obtained. Scans from 76 subjects were analyzed by 2
observers (RH and SG) for assessment of interobserver repeatability (see the
Methods section in this article’s Online Repository).
Statistical analysis
Statistical analyses were performed with IBM SPSS Statistics software for
Windows (version 20.0; IBM, Armonk, NY) and GraphPad Prism software for
Windows (version 6; GraphPad Software, San Diego, Calif). A priori subject
stratification determined based on postbronchodilator FEV1 percent predicted
measurement was performed. Nonparametric and parametric data were
presented as medians (interquartile ranges) or means (SDs), respectively.
Comparisons across groups were analyzed by using parametric and
nonparametric ANOVA with post hoc testing for pairwise comparisons.
Pairwise comparisons were made by using t tests or Mann-Whitney tests, as
appropriate. Statistical significance was reached if the P value was less than
.05. Factor and cluster analysis were carried out with IBM SPSS Statistics
software for Windows (version 20.0). The Kaiser criterion was used to select
the number of the factors, and Ward hierarchical clustering was used to
determine the number of clusters (k). Cluster membership was derived by
using k-means clustering (see the Methods section in this article’s Online
Repository for further details).
RESULTS
Clinical characteristics
The baseline demographics and clinical characteristics of
asthmatic patients, patients with COPD, and healthy subjects
are shown in Table I. Patients with COPD were older and had a
TABLE I. Clinical characteristics of all asthmatic patients, patients with COPD, and healthy control subjects
Asthmatic patients (n 5 171) Patients with COPD (n 5 81) Healthy subjects (n 5 49) Significance (P value)
Age (y) 53 (12.8) 69 (8.16) 57 (13.3) 5E-9*
.07
2E-7
Sexk
Female 51% 33% 39% .03
Male 49% 67% 61%
BMI (kg/m2) 30 (6) 28 (5) 29 (5) .02*
.98
.07
Smoking statusk
Current smoker 4% 20% 4% 7E-17
Exsmoker 34% 80% 45%
Never smoked 62% 0% 51%
Pack years (if smoked) 12.3 (10.6) 50.5 (31.2) 11.7 (9.20) 5E-9*
.99
5E-9
Severe exacerbations per year 2.20 (2.58) 2.18 (2.20) 0 1*
AQLQ 4.97 (1.33) NA NA
ACQ6 1.81 (1.15) NA NA
SGRQ total NA 49.8 (19.1) NA
GOLD/GINA % per group 1/2/3/4 (5) 9/5/19/40 (27) 5/55/29/11 NA
Total IgE (kU/L) 490 (1785) ND 83.6 (217) .13
Blood eosinophil count (3109/L)§ 0.26 (0.15-0.39) 0.22 (0.14-0.29) 0.13 (0.1-0.2) .08*
1E-8
.03
Blood neutrophil count (3109/L)§ 4.42 (3.43-5.77) 4.56 (3.7-5.47) 3.74 (3.16-4.46) 1*
.01
.005
Total sputum cell count (106/g)§ 2.25 (1.13-5.44) 3.92 (1.32-8.46) 1.64 (0.49-5.7) .24*
.51
.04
Sputum (% neutrophils)§ 51.8 (35.3-73) 75.5 (39.8-89.8) 75.1 (48.5-90.3) .007*
.006
1
Sputum (% eosinophils)§ 2.25 (0.5-8.5) 0.75 (0.25-2) 0.25 (0-0.75) 1E-8*
1E-8
.1
Pre-BD FEV1 (% predicted) 78.2 (25.2) 50.5 (17.6) 111 (17.2) 5E-9*
5E-9
5E-9
Post-BD FEV1 (% predicted) 85.3 (24.3) 53.7 (17.2) 113 (18.4) 5E-9*
5E-9
5E-9
Pre-BD FEV1/FVC ratio (%) 68.5 (13.3) 50.6 (10.6) 78.5 (5.55) 5E-9*
9E-7
5E-9
Post-BD FEV1/FVC ratio (%) 70.7 (12.0) 51.7 (10.2) 78.5 (12.6) 5E-9*
1.5E-4
5E-9
BD response (%) 11.3 (15.1) 8.12 (9.56) 1.78 (4.36) .17*
2E-5
.019
KCO (% predicted) 107 (18.4) 74.8 (25.6) 98.9 (13.5) 5E-9*
.08
3E-8
RV/TLC (%) 39.7 (12) 55.1 (12) 34.5 (9) 5E-9*
.04
5E-9
ACQ6, Asthma Control Questionnaire (first 6); AQLQ, Asthma Quality of Life Questionnaire; BD, bronchodilator; BMI, body mass index; FVC, forced vital capacity; GINA,
Global Initiative for Asthma; GOLD, Global Initiative for Chronic Obstructive Lung Disease; NA, not applicable; ND, not done; RV/TLC, residual volume/total lung capacity;
SGRQ, St Georges Respiratory Questionnaire.
Intergroup comparison, parametric (nonparametric) data: The P value for 1-way ANOVA (Kruskal-Wallis test) has been presented unless the ANOVA (Kruskal-Wallis test) result
was significant (P < .05), in which case the P value has been presented for the Tukey (Dunn) test pairwise comparisons: *asthmatic patients versus patients with COPD, asthmatic
patients versus healthy subjects, and patients with COPD versus healthy subjects. Differences in proportions were tested by using the x2 test.
Data are expressed as means (SDs), §medians (interquartile ranges), or kproportions.
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1416 HARTLEY ET ALgreater smoking pack year history, poorer lung function (airflow
limitation defined as postbronchodilator FEV1 percent predicted
<80% or airflow obstruction defined as postbronchodilator
FEV1/forced vital capacity ratio <70%), and higher neutrophilic
airway inflammation compared with that in asthmatic patients.
Asthmatic patients had higher eosinophilic airway inflammation
compared with the other 2 groups. Body mass index of asthmatic
patients was greater than that of patients with COPD. Poorer lung
function was also demonstrated in asthmatic patients compared
with that seen in healthy control subjects.QCT parameters: Comparison between asthmatic
patients, patients with COPD, and healthy subjects
Examples of CT images for asthmatic patients, patients with
COPD, and healthy control subjects are as shown in Fig E1 in this
article’s Online Repository at www.jacionline.org. Airway
morphometry and lung densitometry for asthmatic patients,
patients with COPD, and healthy subjects are summarized in Table
II. Segmental airway morphometry is shown in Tables E1 and E2
in this article’s Online Repository at www.jacionline.org.
Interobserver repeatability for QCT parameters was good to excel-
lent (see the Methods section in this article’s Online Repository).
Mean WA/BSA values were not significantly different among
the 3 groups. However, the mean %WA was increased in both
asthmatic patients and patients with COPD compared with that in
healthy control subjects, with mean LA/BSA values being
significantly smaller in asthmatic patients. The mean LA/BSA
value was less in patients with COPD compared with that in
healthy control subjects, although it did not reach statistical
significance (Fig 1, A and B, and Table II). MLDE/I was increased
in both asthmatic patients and patients with COPD compared with
that in healthy control subjects, with the highest values seen in
patients with COPD (Fig 1, C, and Table II). Perc15 values
were decreased only in patients with COPD, with comparable
values in asthmatic patients and healthy subjects (Fig 1, D, and
Table II). Low-attenuation clusters of less than 2950 HU fractal
dimension (LAC-D2950) value were significantly decreased in
patients with COPD (Fig 1, E). WA of the theoretical airway
with an internal perimeter of 10 mm and %WA of a theoretical
airway with an external perimeter of 20 mm values were
increased in both asthmatic patients and patients with COPD
compared with those in healthy control subjects (Table II).
Age-adjusted comparison of the coprimary QCT parameters
between asthmatic patients, patients with COPD, and healthy
subjects was performed because the mean age of patients with
COPD was higher compared with that of other groups, and all
of the comparisons (1-way ANOVA) remained statistically
significant (P < .001).Univariate analysis to explore the structure-
function relationship in asthmatic patients and
patients with COPD
Correlations between the QCT indices and clinical or
physiologic parameters are shown in Table III and Table E3 in
this article’s Online Repository at www.jacionline.org.
Moderate-to-good correlations were observed between QCT
parameters and lung physiology indices. Perc15 values were
strongly correlated with transfer coefficient (KCO) percent
predicted values in patients with COPD and MLDE/I, withresidual volume/total lung capacity (as a percentage) in all 3
groups. Airflow obstruction was most strongly associated with
Perc15 and MLDE/I values, with a weaker association with %
WA and LA/BSA values in asthmatic patients and patients with
COPD (Table III). Airflow limitation in asthmatic patients was
strongly correlated with mean %WA and weakly with MLDE/I
and Perc15 values. In contrast, airflow limitation in patients
with COPD was most strongly associated with MLDE/I and, to a
lesser extent, Perc15 and %WA values (Fig 2 and Table III).
Sputum neutrophil counts showed positive correlations with
mean %WA values in asthmatic patients, and sputum eosinophil
counts were inversely correlated with mean %WA values in
patients with COPD. Correlations were also observed between
(1) airway narrowing and asthma control and (2) between
MLDE/I and COPD-related quality of life (see Table E3).Multiple regression analysis to explore structure-
function relationships in asthmatic patients and
patients with COPD
Multiple linear regression analysis in asthmatic patients
showed that mean %WA, MLDE/I, and Perc15 values made a
statistically significant contribution to the regression model for
prediction of postbronchodilator FEV1 percent predicted, with
mean %WA values making the strongest unique contribution.
Multiple linear regression analysis in patients with COPD showed
that MLDE/I and mean %WA values made a statistically
significant contribution to the regression model for prediction
of postbronchodilator FEV1 percent predicted, with MLDE/I
making the strongest unique contribution (Table IV).Univariate and multiple regression analysis to
explore structure-function relationships in
asthmatic patients and patients with COPD with
airflow limitation
A subset of asthmatic patients and patients with COPD with
postbronchodilator FEV1 percent predicted values of less than
80% were assessed for correlations between QCT and lung
physiology parameters (Fig E2 and Table E4 in this article’s
Online Repository at www.jacionline.org). Correlations between
KCO percent predicted or residual volume/total lung capacity (as
a percentage) and Perc15 or MLDE/I values were stronger
compared with previous analysis of unselected patients (see
Table E4). Postbronchodilator FEV1 percent predicted values
showed correlations with MLDE/I in asthmatic patients and with
both MLDE/I and Perc15 values in patients with COPD. Multiple
linear regression analysis demonstrated that in this subset of
patients with COPD,MLDE/I made the strongest unique contribu-
tion to the regression model for prediction of postbronchodilator
FEV1 percent predicted (see Table E5 in this article’s Online
Repository at www.jacionline.org). Multiple regression analysis
was not performed in asthmatic patients because univariate
analysis only showed correlation between postbronchodilator
FEV1 percent predicted and MLDE/I.Asthma and COPD subgroup analysis
We stratified asthmatic patients and patients with COPD into 3
subgroups each based on postbronchodilator FEV1 percent
predicted: (1) greater than 80% (asthma, n 5 101; COPD,
TABLE II. Airway morphometry and lung densitometry of asthmatic patients, patients with COPD, and healthy control subjects
Asthmatic patients (n 5 171) Patients with COPD (n 5 81) Healthy subjects (n 5 49) Significance (P value)
Mean LA/BSA (mm2/m2) 11.0 (2.58) 11.3 (3.02) 12.3 (2.75) .67*
.006
.08
Mean TA/BSA (mm2/m2) 28.5 (5.32) 29.3 (6.20) 30.5 (5.40) .09
Mean WA/BSA (mm2/m2) 17.5 (2.84) 18.1 (3.31) 18.1 (2.76) .29
Mean %WA 62.5 (2.19) 62.7 (2.26) 60.3 (2.17) .79*
3E-8
4E-8
MLDE/I 0.852 (0.061) 0.922 (0.037) 0.816 (0.066) 5E-9*
5E-4
5E-9
RVC 229.3 (12.4) 212.2 (9.36) 236.8 (10.2) 5E-9*
3E-4
5E-9
Insp VI2950 12.17 23.32 11.40 5E-9*
.79
5E-9
Exp VI2856 20.27 47.57 14.81 5E-9*
<.05
5E-9
CTLVE/I 0.58 (0.13) 0.67 (0.18) 0.51 (0.12) 5E-9*
.009
8E-9
Perc15 (HU) 2937 (22.7) 2964 (19.62) 2937 (17.07) 5E-9*
1
5E-9
LAC-D2950 1.96 (0.104) 1.810 (0.132) 1.989 (0.107) 6E-9*
.26
1E-8
Pi10 WA (mm2) 15.1 (1.42) 15.0 (1.46) 14.4 (1.10) .89*
.011
.06
Po20 %WA 56.1 (2.57) 56.4 (2.97) 54.6 (1.71) .7*
.001
2E-4
%WA (no. [%] above)§ 27 (15.8%) 13 (7.60%) NA 1.0
MLDE/I (no. [%] above)§ 8 (4.68%) 22 (27.16%) NA 1E-8
Perc15 (no. [%] below)k 7 (4.09%) 26 (32.1%) NA 1E-8
CTLVE/I, Computed tomographic lung volume expiratory/inspiratory ratio; Exp VI2856, expiratory voxel index less than2856 HU; Insp VI2950, inspiratory voxel index less than
2950 HU; Pi10, Wall area of theoretical airway with an internal perimeter of 10 mm; Po20 %WA, Percentage wall area of a theoretical airway with an external perimeter of
20 mm; RVC, Relative voxel change.
Intergroup comparison: The P value for 1-way ANOVA has been presented unless the ANOVA result was significant (P < .05), in which case the P value has been presented for
Tukey test pairwise comparisons: *asthmatic patients versus patients with COPD, asthmatic patients versus healthy subjects, and patients with COPD versus healthy subjects.
Data are expressed as means (SDs), §greater than 2 SDs of healthy control subjects, and kless than 2 SDs of healthy control subjects.
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(3) less than 50% (asthma, n 5 14; COPD, n 5 34). Because
only 5 patients with COPD had a postbronchodilator FEV1
percent predicted value of greater than 80%, they were excluded
from further analyses. The asthmatic patients with postbronchodi-
lator FEV1 percent predicted values of greater than 80%
compared with healthy control subjects have significantly greater
mean %WA values, with no significant difference in MLDE/I or
Perc15 values (Fig 3, A-D). In the asthma subgroup with
postbronchodilator FEV1 percent predicted values of 50% to
80%, mean %WA values were greater and LA/BSA values were
lower compared with those in the subgroup with postbronchodi-
lator FEV1 percent predicted values of greater than 80% (Fig 3,
A and B). The asthma subgroup with FEV1 percent predicted
values of less than 50% did not show a significant difference inairway morphometry compared with the other asthma subgroups.
In patients with COPD, mean %WA and LA/BSAvalues were not
significantly different between the subgroups with postbroncho-
dilator FEV1 percent predicted values of 50% to 80% versus
less than 50%. In subgroups with postbronchodilator FEV1
percent predicted values of 50% to 80%, asthmatic patients
have greater mean %WA and smaller LA/BSA values compared
with those in patients with COPD (Fig 3, A and B).
In both asthmatic patients and patients with COPD, subgroups
with lower postbronchodilator FEV1 percent predicted values
had higher MLDE/I and lower Perc15 values (Fig 3, C and D).
The asthma and COPD subgroups with a similar degree of
lung function impairment showed no significant difference in
MLDE/I values (Fig 3, C). Patients with COPD with postbroncho-
dilator FEV1 percent predicted values of 50% to 80% showed
FIG 1. Dot plots of airway morphometric and densitometric QCT parameters for all asthmatic patients,
patientswithCOPD, andhealthy control subjects:A,mean%WA;B,meanLA/BSA;C,MLDE/I;D,densitometry
(Perc15); and E, fractal index (LAC-D2950).
TABLE III. Correlations between clinical outcomes and QCT parameters
Postbronchodilator FEV1
(% predicted),
asthmatic patients
Postbronchodilator FEV1
(% predicted),
patients with COPD
Postbronchodilator
FEV1/FVC (%),
asthmatic patients
Postbronchodilator
FEV1/FVC (%),
patients with COPD
Mean LA/BSA (mm2/m2) 0.324 0.241* 0.218 0.082
Mean TA/BSA (mm2/m2) 0.287 0.238* 0.171* 0.084
Mean WA/BSA (mm2/m2) 0.247 0.226* 0.126 0.083
Mean %WA 20.417 20.248* 20.343 20.121
MLDE/I 20.303 20.697 20.402 20.729
Perc15 (HU) 0.178* 0.434 0.408 0.554
LAC-D2950 0.190* 0.180 0.234 0.245*
FVC, Forced vital capacity.
Pearson correlation coefficient: *P < 0.05 and P < .005.
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patients with a similar degree of lung function impairment
(Fig 3, D). In subgroups with postbronchodilator FEV1 percent
predicted values of less than 50%, patients with COPD and
asthmatic patients showed no significant difference in Perc15
values (Fig 3, D), but the LAC-D2950 value was significantly
decreased in patients with COPD (Fig 3, E).Unbiased phenotyping of patients with airway
disease (asthma and COPD) by using factor analysis
of QCT parameters
We undertook a de novo factor analysis of QCT parameters in
asthmatic patients or patients with COPD, which revealed the
3 components with the strongest loading variables as mean
LA/BSA, Perc15, and MLDE/I values (see Table E6 in this
article’s Online Repository at www.jacionline.org). A cluster
analysis using these 3 highest loading variables revealed 3 clusters
(see Fig E3 and Table E7 in this article’s Online Repository at
www.jacionline.org). The 3 clusters had mild (asthma, n 5 40;
COPD, n 5 2), moderate (asthma, n 5 94; COPD, n 5 24), and
severe (asthma, n5 25; COPD, n5 47) lung function impairment,
respectively, with decreased Perc15 and increasedMLDE/I values,
which are a particular feature of cluster 3.DISCUSSION
We describe the airwaymorphometry and lung densitometry of
asthmatic patients and patients with COPD with reference to
healthy control subjects and their relationship to lung function.
We found that proximal airway remodeling and air trapping were
features of both asthma and COPD. Airway WA, expressed as a
percentage of total area (%WA), was increased in patients with
either disease. Air trapping in patients with COPD was more
severe compared with that in asthmatic patients. Emphysema was
only seen in patients with COPD, with Perc15 values being
significantly lower compared with those in other groups.
Comparable Perc15 values between asthmatic patients and
healthy subjects confirm the absence of emphysema in asthmatic
patients. Assessment of structure-function relationships revealed
a significant contribution of proximal airway remodeling, which
was represented by the percentage of WA and air trapping, as
represented by MLDE/I, in the prediction of airflow limitation in
asthmatic patients. In contrast, similar assessment in patients
with COPD showed that only QCT-determined air trapping and
emphysema contributed to airflow limitation. Both disease
groups, when further stratified by the degree of lung function
impairment, showed that in the subgroup with postbronchodilator
FEV1 percent predicted values of less than 80%, air trapping
remained a significant predictor of lung function impairment.
FIG 2. Scatter plot and linear regression of asthmatic patients (gray circles) and patients with COPD (black
squares) showing the relationship between FEV1 percent predicted values and the QCT morphometric and
densitometric measures: A, mean %WA; B, mean LA/BSA; C, MLDE/I; and D, densitometry (Perc15).
TABLE IV. Multiple regression to determine the strongest
independent QCT parameters of postbronchodilator FEV1
percent predicted (ie, the dependent variable)
Model R2 B SE b
Significance
(P value)
Asthmatic patient
%WA 0.254 23.771 0.778 20.344 3E-6
MLDE/I 2108.021 28.283 20.271 2E-4
Perc15 (HU) 0.190 0.074 .0181 .01
Patients with COPD
%WA 0.542 21.447 0.644 20.185 .03
MLDE/I 2283.191 42.260 20.607 5E-9
Perc15 (HU) 0.151 0.079 0.173 .06
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contribute to prediction of airflow limitation.
With asthma and COPD combined in a factor and cluster
analysis, the findings were consistent with our a priori stratifica-
tion. Factor analysis revealed 3 components, with the highest
loading factors being measures of proximal airway narrowing,
air trapping, and emphysema, and cluster analysis demonstrated
3 clusters that could be distinguished by their degree of airflow
obstruction.
Changes in proximal airway geometry in patients with COPD
are common, and our findings of increased mean segmental %WA
values compared with those in control subjects was consistent
with previous studies.20 This is consistent with proximal airway
remodeling in asthmatic patients in the current and previous
studies.8,21 Diaz et al22 have also demonstrated proximal airway
lumen narrowing in patients with mild COPD. No significant
difference was seen in proximal airway remodeling between
asthmatic patients and patients with COPD, which is consistent
with previous literature.23 Conversely, other studies reportsignificantly greater proximal airway remodeling in asthmatic pa-
tients compared with that seen in patients with COPD.24,25 In our
study the asthma subgroup with postbronchodilator FEV1 percent
predicted values of 50% to 80% have greater mean %WA and
smaller LA/BSA values compared with those in patients with
COPD, with a similar degree of airflow limitation. Moreover,
among airway disease subgroups with postbronchodilator FEV1
percent predicted values of less than 50% when compared with
those in healthy control subjects, proximal airway lumen narrow-
ing was seen in patients with COPD but not in asthmatic patients.
These findings highlight the heterogeneity of airway disease and
the importance ofmultilevel disease phenotyping and suggest that
proximal lumen dimensions in asthmatic patients with severe
airflow impairment might become relatively dilated, perhaps to
compensate for progressive small-airway disease.
Results from COPD gene studies have shown that physiologic
airway obstruction correlates with both QCT air-trapping
indices26,27 and QCT-determined emphysema,26 with the former
showing stronger correlations. Similarly, in asthmatic patients
QCT-determined air trapping has been associated with increased
disease severity.28 Emphysema in asthmatic patients has not been
extensively studied. However, a few studies have suggested that
emphysema in asthmatic patients is likely secondary to smok-
ing.29 In our study we did not find any evidence of emphysema
in asthmatic patients because the Perc15 value was comparable
with that in healthy control subjects. Perc15 values in the asthma
subgroup with severe airflow limitation were similar to those in
the COPD subgroup with matched airflow limitation, which
might suggest that these asthmatic patients have emphysema.
However, high fractal dimension of low-attenuation clusters in
the asthma subgroup compared with the COPD subgroup indicate
that Perc15 values in this cohort represent air trapping rather than
emphysema. Other researchers have found low attenuation on CT
scans in asthmatic patients, which is comparable with results seen
in patients with emphysema30,31 and has been attributed to
FIG 3. Dot plots of airway morphometric and densitometric QCT parameters for asthmatic patients
(black circles, FEV1 percent predicted <50%; gray circles, 50% to 80%; open circles, >80%), patients with
COPD (black squares, FEV1 percent predicted <50%; gray squares, 50% to 80%), and healthy control subjects
(open triangles): A, mean %WA; B, mean LA/BSA; C, MLDE/I; D, densitometry (Perc15); and E, fractal index
(LAC-D2950).
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rather than the alveolar disruption seen in patients with
COPD.32 Therefore the fractal dimension of the low-attenuation
cluster is an important QCT parameter in differentiating CT
low attenuation secondary to emphysema and air trapping.31,33
The findings presented here for COPD are consistent with those
of previous studies and support the view that airflow limitation
and obstruction are due to a combination of small-airway
obliteration and emphysema.34 We found that changes in
proximal airway geometry contribute to postbronchodilator
FEV1 percent predicted values in the multiple regression model
for the whole COPD cohort. This is in keeping with previous
studies, which have shown that both emphysema and proximal
airway remodeling contribute to the prediction of lung function
in patients with COPD.35 Proximal airway geometry, particularly
airway lumen narrowing, was associated with airflow limitation
in asthmatic patients. However, when the asthma subgroup with
airflow limitation was assessed, only air trapping was a significant
predictor of lung function, suggesting that small-airway disease is
particularly important in this group. This might be important for
our understanding of disease pathogenesis, monitoring the
response to therapy and identification for therapeutic targets.
Importantly, emphysema is absent in asthmatic patients withvarying degrees of severity and smoking history. Whether the
absence of emphysema is a critical distinction between the
pathogenesis of asthma and COPD or simply a consequence of
the classification of COPD is unclear. Air trapping determined
by using QCT was closely related to residual volume/total lung
capacity (as a percentage) in both asthmatic patients and patients
with COPD, and QCT-determined emphysema was related to
KCO percent predicted values in patients with COPD. Even
though important differences were observed between asthmatic
patients and patients with COPD, there was marked heterogeneity
within both disease groups, supporting the view that classification
of obstructive airways disease needs to consider multiple
dimensions of the disease rather than rely on simple disease
labels.
Beyond the associations between QCT and lung function, we
explored the relationship between QCTand sputum cell counts or
health status. The clinical significance of the weak correlations
seen between airway inflammation and Perc15 or low-attenuation
cluster of less than 2950 HU fractal dimension values in
asthmatic patients is uncertain. Proximal airway narrowing in
asthmatic patients was associated with an increased blood
neutrophil counts. Previous studies have reported similar
relationships in asthmatic patients, with airway remodeling and
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between proximal airway morphometry and health status in
asthmatic patients, with decreased WA and LA values associated
with poorer asthma control and health status. In patients with
COPD, increased air trapping, but neither proximal wall
remodeling nor emphysema, was weakly associated with poorer
health status. How closely changes in airway morphometry or
densitometry over time or in response to interventions are related
to these clinical outcomes needs to be investigated further.
The major limitation of this report is that it is a cross-sectional
study, and therefore neither the natural history of disease nor the
temporal repeatability of the measures was examined. In previous
reports QCTwas highly repeatable, and thereforewe are confident
that themeasures are robust, but longitudinal studies are needed to
study the dynamic relationships between airway structure and
function. Patients with COPD were older than those with asthma
and healthy control subjects, and therefore age and disease effects
need to be considered. Importantly, in our study population age
did not influence the differences in QCT parameters between
groups for any of the coprimary QCT outcome measures.
Although this is the largest study to date comparing QCT
parameters in asthmatic patients and patients with COPD, to
further explore the heterogeneity of QCT in both of these groups,
further larger studies that include complex phenotyping are
required. The investigation of the relationship between QCT
and airway inflammation was limited to sputum cell counts and
needs to be extended in larger studies of airway inflammation and
remodeling determined from bronchial biopsy specimens. In
addition, the effect of disease exacerbations and exposure to
pathogens on structure-function relationships needs to be
explored further.
In conclusion, proximal airway remodeling and air trapping are
QCT features shared by asthmatic patients and patients with
COPD compared with healthy control subjects, but emphysema is
largely restricted to patients with COPD. In both disease groups
air trapping is an independentmajor determinant for lung function
impairment, with an additional important contribution from
proximal airway remodeling, particularly in asthmatic patients
with mild lung function impairment.
We thank the respiratory research nurses for help with clinical character-
ization of patients and our colleagues in the Radiology Department at
Glenfield Hospital, Leicester, United Kingdom, for coordinating CT scans.
Clinical implications: Comprehensive comparisons of QCT pa-
rameters between asthmatic patients and patients with COPD
and their association with lung function and clinical outcomes
might further our understanding of disease pathogenesis, help
monitor disease progression, and improve phenotyping of
airway disease.REFERENCES
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CT
Volumetric whole lung scans were obtained by using a Siemens Sensation
16 scanner (163 0.75–mm collimation, 1.5-mm pitch, 120 kVp, 40 mAs, 0.5-
second rotation time, and scanning field of view of 500 mm). Scans were
obtained at full inspiration (near total lung capacity) and at the end of
expiration (near functional residual capacity). All subjects were coached in
breath-holding techniques and practiced breath holding immediately before
scanning. All asthmatic patients and patients with COPDwere scanned within
60 minutes of receiving 400 mg of salbutamol through a spacer or 2.5 mg of
nebulized salbutamol. Images were reconstructed with a slice thickness of
0.75 mm at a 0.5-mm interval by using B35f kernal. Postprocessing was
performed with the fully automated software Apollo (VIDA Diagnostics).
QCT parameters obtained included the following: morphometry measured
in square millimeters, LA, TA, WA (TA2LA), and%WA

1003

ðTA2LAÞ
TA

.
Air-trappingmeasures wereMLDE/I measured in Hounsfield units and relative
voxel change Exp((VI2856) 2 (VI2950)) 2 Insp((VI2856) 2 (VI2950)).
Emphysema was quantified by using Perc15. Fractal dimensions of the
low-attenuation clusters on inspiratory (LAC-D2950) and expiratory
(low-attenuation clusters less than 2856 HU fractal dimension value) scans
were also measured. All morphometric measures were corrected for BSA in
square millimeters per square meter
 ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
heightðcmÞ3weightðkgÞ
3600
q !
. Density mea-
sures were corrected to account for scanner variability over time, as previously
published.E1 A representative example of an inspiratory and expiratory scan,
airway reconstruction from the inspiratory scan, and densitometric maps from
both the inspiratory and expiratory scans are as shown Fig E1.
Interobserver repeatability of coprimary QCT
parameters
Interobserver repeatability was assessed (Cronbach a intraclass correlation
[ICC]) between 2 observers (RH and SG) in 76 subjects for Perc15 (ICC,0.996; P < .001), MLD at inspiration (ICC, 0.997; P < .001) and expiration
(ICC, 0.997; P < .001), RB1 LA (ICC, 0.873; P < .001), and TA (ICC,
0.873; P < .001).
Factor and cluster in the COPD and severe asthma
cohorts
We undertook de novo cluster analysis on the patients with COPD and asth-
matic patients together by using the same methodology carried out in Gupta
et alE1 but using the QCT variables as follows: (1) mean LA/BSA; (2) mean
WA/BSA; (3) mean total area (TA)/BSA; (4) mean%WA; (5) expiratory voxel
index 2856; (6) MLDE/I ratio; (7) voxel index change of percent voxels be-
tween 2950 HU and 2856 HU on paired inspiratory and expiratory CT
scan; (8) expiratory fractal dimension of low attenuation cluster at threshold
of 2856 HU; (9) inspiratory voxel index 2950; (10) Perc15; and (11)
inspiratory fractal dimension of low attenuation cluster at threshold of
2950 HU.
QCTvariables listedwere first used in a factor analysis, with 3 factors being
found, allowing for 81% of the variation. The Kaiser criteria to determine the
number of factors were used while picking all factors with an eigenvalue of
greater than 1. Varimax rotation was also used to determine the best clinical
interpretable factors, as shown in Table E6. The highest loading variables on
each factor were taken forward into a cluster analysis. These were mean LA
adjusted for BSA, Perc15, and MLDE/I values.
First hierarchic cluster analysis was applied to determine the number of
clusters that best fit the data. Then the number of clusters determined (3 in this
case, see Fig E3) was inputted into a k-means cluster analysis to determine
cluster membership for each patient. Cluster demographics and comparisons
are as shown in Table E7.REFERENCE
E1. Gupta S, Hartley R, Khan UT, Singapuri A, Hargadon B, Monteiro W, et al. Quan-
titative computed tomography-derived clusters: redefining airway remodeling in
asthmatic patients. J Allergy Clin Immunol 2014;133:729-38.e18.
FIG E1. Visual representation of QCT parameters with CT inspiratory and expiratory axial slices (first 2
columns) illustrates qualitative differences of increased inspiratory volume, emphysema, and air trapping
in patients with disease versus healthy control subjects. Column 3 shows airways grown by the
postprocessing software, which are reduced in patients with disease. The fourth column shows low
attenuating clusters (LACs) of less than 2950 HU in inspiration, representing areas of emphysema, and
the final column shows the LACs of less than 2856 in expiration, representing areas of air trapping.
J ALLERGY CLIN IMMUNOL
MAY 2016
1422.e2 HARTLEY ET AL
FIG E2. Scatter plot and linear regression of subjects with an FEV1 percent predicted value of less than 80%
with asthma (gray circles) and COPD (black squares), showing the relationship between FEV1 percent
predicted and QCT morphometric and densitometric measures: A, mean %WA; B, mean LA/BSA;
C, MLDE/I; and D, densitometry (Perc15).
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FIG E3. A, Dendrogram to which the number of clusters was determined (k 5 3). B and C, Two representa-
tions of the clusters on z scores of 3 QCT variables: MLDE/I, Perc15, and LA/BSA. Small dots represent
individual patients, and large spheres represent sample sizes of clusters centered on their multivariate
cluster means.
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TABLE E1. LA/BSA for segmental airways in asthmatic patients, patients with COPD, and healthy control subjects
Asthmatic patients Patients with COPD Healthy subjects Significance (P value)
RB1 LA/BSA (mm2/m2) 11.3 (4.04) 10.6 (3.68) 11.8 (3.95) .25
RB2 LA/BSA (mm2/m2) 11.4 (3.87) 11.2 (4.26) 12.1 (4.34) .42
RB3 LA/BSA (mm2/m2) 15.0 (5.71) 15.3 (5.64) 16.1 (4.58) .48
RB4 LA/BSA (mm2/m2) 8.42 (3.36) 8.65 (3.12) 9.17 (3.35) .37
RB5 LA/BSA (mm2/m2) 9.38 (3.01) 9.98 (4.41) 10.9 (2.92) .42*
.02
.29
RB6 LA/BSA (mm2/m2) 13.8 (6.51) 15.9 (13.9) 16.0 (6.95) .19
RB7 LA/BSA (mm2/m2) 8.86 (4.08) 8.07 (3.07) 9.27 (3.22) .19
RB8 LA/BSA (mm2/m2) 10.4 (3.32) 10.3 (3.05) 11.9 (3.06) .98*
.02
.02
RB9 LA/BSA (mm2/m2) 8.83 (3.77) 8.20 (3.35) 9.96 (3.25) .41*
.13
.02
RB10 LA/BSA (mm2/m2) 11.9 (3.84) 11.84 (4.42) 13.38 (3.71) .07
LB1 LA/BSA (mm2/m2) 8.71 (3.11) 8.43 (3.34) 9.92 (3.18) .81*
.07
.03
LB2 LA/BSA (mm2/m2) 6.04 (2.67) 6.45 (3.23) 7.66 (4.16) .63*
.007
.10
LB3 LA/BSA (mm2/m2) 13.6 (4.65) 14.4 (5.50) 14.2 (4.35) .44
LB4 LA/BSA (mm2/m2) 8.26 (3.25) 8.08 (3.53) 8.77 (3.83) .54
LB5 LA/BSA (mm2/m2) 7.58 (2.80) 8.11 (3.09) 8.39 (2.27) .16
LB6 LA/BSA (mm2/m2) 17.1 (6.86) 18.6 (7.74) 20.4 (5.63) .32*
.01
.34
LB112 LA/BSA (mm2/m2) 13.6 (5.32) 15.3 (7.13) 15.7 (5.69) .08*
.08
.94
LB8 LA/BSA (mm2/m2) 12.3 (3.96) 13.5 (5.67) 15.0 (5.28) .16*
.002
.22
LB9 LA/BSA (mm2/m2) 10.7 (4.46) 10.4 (4.68) 12.7 (4.83) .87*
.03
.02
LB10 LA/BSA (mm2/m2) 12.7 (4.40) 12.8 (4.89) 14.1 (4.33) .17
Right segmental mean LA/BSA (mm2/m2) 10.9 (2.62) 10.8 (3.57) 12.0 (2.62) .99*
.04
.06
Left segmental mean LA/BSA (mm2/m2) 11.0 (2.79) 11.4 (3.44) 12.4 (3.52) .66*
.02
.18
Data are expressed as means (SDs). Intergroup comparison: The P value for 1-way ANOVA has been presented unless the ANOVA result was significant (P < .05), in which case
the P value has been presented for Tukey test pairwise comparisons: *asthmatic patients versus patients with COPD, asthmatic patients versus healthy subjects, and patients with
COPD versus healthy subjects.
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TABLE E2.%WA for segmental airways for asthmatic patients,
patients with COPD, and healthy control subjects
Asthmatic
patients
Patients
with COPD
Healthy
subjects
Significance
(P value)
RB1 %WA 62.7 (3.97) 64.0 (3.54) 61.3 (3.39) .13*
.03
.001
RB2 %WA 61.8 (3.41) 62.3 (3.61) 59.4 (3.65) .54*
1E-4
2E-5
RB3 %WA 60.1 (3.67) 60.4 (3.91) 57.9 (3.98) .79
.001
.001
RB4 %WA 63.3 (3.63) 63.7 (3.17) 61.7 (3.23) .65*
.02
.005
RB5 %WA 62.8 (3.06) 62.6 (3.33) 60.3 (2.38) .93*
6E-6
2E-4
RB6 %WA 61.4 (4.52) 61.4 (4.53) 58.1 (3.95) 1*
1E-4
.001
RB7 %WA 64.6 (3.71) 66.0 (2.72) 63.3 (3.19) .02*
.07
2E-4
RB8 %WA 62.8 (3.45) 64.0 (3.16) 60.9 (2.89) .04*
.001
2E-6
RB9 %WA 63.6 (3.23) 64.4 (2.93) 62.1 (3.56) .28*
.01
.001
RB10 %WA 61.2 (3.30) 61.6 (3.44) 59.3 (3.43) .71*
.002
.001
LB1 %WA 63.9 (2.88) 64.3 (2.84) 62.1 (2.68) .61*
.001
1E-4
LB2 %WA 64.8 (3.04) 64.6 (2.98) 62.6 (4.12) .94*
4E-4
.004
LB3 %WA 60.5 (3.92) 60.9 (4.42) 58.9 (3.35) .8*
.04
.02
LB4 %WA 62.4 (3.65) 63.1 (3.47) 61.1 (3.73) .53*
.08
.02
LB5 %WA 63.6 (3.21) 63.8 (2.97) 62.1 (2.45) .87*
.007
.006
LB6 %WA 59.4 (4.56) 59.0 (4.78) 56.1 (3.41) .85*
4E-5
.001
LB112 %WA 62.1 (4.17) 61.3 (4.54) 59.8 (4.34) .42*
.005
.14
LB8 %WA 62.5 (3.60) 62.1 (4.30) 59.6 (4.08) .73*
4E-5
.003
LB9 %WA 63.4 (3.65) 63.3 (3.42) 61.4 (3.84) .96*
.002
.01
(Continued)
TABLE E2. (Continued)
Asthmatic
patients
Patients
with COPD
Healthy
subjects
Significance
(P value)
LB10 %WA 61.1 (3.88) 61.3 (3.70) 58.7 (3.39) .87*
3E-4
4E-4
Right segmental
mean %WA
62.50 (2.29) 62.9 (2.45) 60.4 (2.24) .53*
2E-7
7E-8
Left segmental
mean %WA
62.42 (2.34) 62.4 (2.36) 60.3 (2.28) .98*
9E-8
4E-6
Data are expressed as means (SDs). Intergroup comparison: The P value for 1-way
ANOVA has been presented unless the ANOVA result was significant (P < .05), in
which case the P value has been presented for Tukey test pairwise comparisons:
*asthmatic patients versus patients with COPD, asthmatic patients versus healthy
subjects, and patients with COPD versus healthy subjects.
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TABLE E3. Correlations between clinical outcomes and QCT parameters for asthmatic patients (upper values) and patients with
COPD (lower values)
RV/TLC
KCO
(% predicted)
Sputum
eosinophils (%)*
Sputum
neutrophils (%)*
Blood
eosinophils*
Blood
neutrophils* AQLQ* ACQ6*
SGRQ
total*
Mean LA/BSA (mm2/m2) 20.147
20.171
20.163
20.089
0.031
0.121
20.134
0.036
20.019
20.033
20.183
20.11
0.113
NA
20.152
NA
NA
20.034
Mean TA/BSA (mm2/m2) 20.115
20.198
20.153
20.084
0.044
0.096
20.120
0.042
20.011
20.033
20.188
20.101
0.135
NA
20.164*
NA
NA
20.040
Mean WA/BSA (mm2/m2) 20.078
20.217
20.153
20.075
0.064
0.086
20.119
0.064
20.003
20.027
20.196
20.28
0.171
NA
20.179*
NA
NA
20.059
Mean %WA 0.237
0.130
0.201
0.053
20.003
20.236
0.094
20.026
0.037
20.07
0.128
0.216
20.049
NA
0.120
NA
NA
0.010
MLDE/I 0.481
0.510
20.146
20.466
0.026
20.170
0.119
0.185
0.081
0.033
0.053
0.135
20.015
NA
0.030
NA
NA
0.230
Perc15 (HU) 20.196
20.271
20.013
0.477
20.239
0.047
0.084
0.005
20.007
0.142
0.022
20.018
20.028
NA
0.001
NA
NA
0.108
LAC-D2950 20.162
20.170
0.083
0.484
0.272
0.181
20.083
0.193
0.156
0.025
20.074
20.021
0.006
NA
0.024
NA
NA
20.061
ACQ6, Asthma Control Questionnaire (first 6); AQLQ, Asthma Quality of Life Questionnaire; NA, not applicable; RV/TLC, residual volume/total lung capacity; SGRQ, St Georges
Respiratory Questionnaire.
Pearson correlation coefficient for parametric data are shown. *Otherwise, the Spearman correlation coefficient for nonparametric data is shown.
P < .05 and P < .005.
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TABLE E4. Correlations between QCT parameters and clinical outcomes in asthmatic patients (n 5 70, upper values) and patients
with COPD (n 5 77, lower values) with FEV1 percent predicted values of less than 80%
Post-BD FEV1
(% predicted)
Post-BD
FEV/FVC
(%) RV/TLC
KCO
(% predicted)
Sputum
eosinophils
(%)*
Sputum
neutrophils*
Blood
eosinophils*
Blood
neutrophils* AQLQ* ACQ6* SGRQ*
Mean LA/BSA
(mm2/m2)
20.072
0.158
20.085
0.043
0.049
20.106
0.001
20.120
0.189
0.043
0.093
0.047
0.143
20.033
0.134
20.096
0.085
NA
20.153
NA
NA
20.035
Mean TA/BSA
(mm2/m2)
20.069
0.164
20.110
0.044
0.082
20.145
20.007
20.129
0.203
0.021
0.092
0.042
0.152
20.045
20.140
20.087
0.112
NA
20.170
NA
NA
20.052
Mean WA/BSA
(mm2/m2)
0.070
0.164
20.137
0.045
0.118
20.179
20.007
20.134
0.215
0.024
0.110
0.052
0.169
20.044
20.160
20.02
0.172
NA
20.208
NA
NA
20.079
Mean %WA 0.020
20.161
20.060
20.094
0.057
0.046
0.064
0.043
20.190
20.153
20.053
20.083
20.101
0.048
20.103
0.186
0.068
NA
0.004
NA
NA
20.026
MLDE/I 20.455
20.657
20.558
20.714
0.611
0.482
20.254
20.422
0.138
20.135
0.030
0.244
0.066
0.040
20.158
0.187
0.168
NA
20.183
NA
NA
0.254
Perc15 (HU) 0.233
0.458
0.493
0.559
20.242
20.264
20.021
0.467
20.042
0.031
0.057
20.035
0.098
0.132
20.118
20.025
20.157
NA
0.089
NA
NA
0.074
Mean fractal -950 20.007
2.239
20.149
20.248
0.048
0.202
20.019
20.481
0.216
20.258
0.038
0.289
0.183
0.077
20.02
20.002
0.326
NA
20.340
NA
NA
0.133
ACQ6, Asthma Control Questionnaire (first 6); AQLQ, Asthma Quality of Life Questionnaire; BD, bronchodilator; FVC, forced vital capacity; NA, not applicable; RV/TLC, residual
volume/total lung capacity; SGRQ, St Georges Respiratory Questionnaire.
Pearson correlation coefficient for parametric data is shown. *Otherwise, the Spearman correlation coefficient for nonparametric data is shown.
P < .05 and P < .005.
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TABLE E5. Multiple regression to determine the strongest
independent QCT parameters of FEV1 percent predicted in
those subjects with FEV1 percent predicted values of less
than 80%
Model R2 B SE b Significance (P value)
Patients with COPD
MLDE/I 0.473 2241 41.5 20.567 .001
Perc15 (HU) 0.165 0.073 0.221 .03
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TABLE E6. Factor analysis of QCT variables with combined
cohort of both asthmatic patients and patients with COPD
Factors
1 2 3
Mean LA/BSA (mm2/m2) 0.99 0.02 20.05
Mean TA/BSA (mm2/m2) 0.94 0.02 0.00
Mean WA/BSA (mm2/m2) 0.98 0.02 20.02
Mean %WA 20.78 0.03 0.16
Insp VI2950 20.06 0.73 0.60
MLDE/I 20.04 0.33 0.87
Mean voxel index change 20.18 20.04 0.87
Mean fractal 856 0.15 0.57 0.38
Insp VI2950 20.08 0.92 0.08
Perc15 (HU) 0.06 20.94 0.13
Mean fractal 950 0.07 0.75 0.18
The 3 factors accounted for 81% of variation of all variables.
Insp VI2950, Inspiratory voxel index less than 2950 HU.
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TABLE E7. Demographics and both clinical CT and QCT of clusters in a combined cohort of asthmatic patients and patients with
COPD
Cluster 1: asthmatic patients,
n 5 42; patients with
COPD, n 5 2
Cluster 2: asthmatic patients,
n 5 94; patients with
COPD, n 5 24
Cluster 3: asthmatic patients,
n 5 25; patients with
COPD, n 5 47
Significance
(P value)
Age (y) 49.7 (13.1) 58.0 (12.4) 62.8 (12.5) 6E-7*
.03
.001
Sex§
Female 73.8% 27.8% 45.8% 1E-5
Male 26.2% 72.2% 54.2%
BMI (kg/m2) 29.0 (6.0) 28.9 (5.7) 28.7 (6.3) .97
Smoking statusk
Current smoker 4.8% 9.7% 9.3% 2E-4
Exsmoker 31% 68.1% 44.9%
Never smoked 64.3% 22.2% 45.7%
Pack years (if smoked) 4.8 (10.6) 13.8 (28.0) 34.3 (36.7) 2E-7*
3E-6
.2
Severe exacerbations per year 2 (3) 2 (2) 2 (2) .51
Blood eosinophil count (3109/L)§ 0.28 (0.14-0.42) 0.25 (0.15-0.36) 0.23 (0.14-0.29) .29
Blood neutrophil count (3109/L)§ 4.6 (3.4-5.7) 4.4 (3.6-5.7) 4.6 (3.6-5.7) 1
Total sputum cell count (106/g)§ 1.77 (0.92-7.84) 2.33 (1.01-5.10) 3.37 (1.23-7.00) .27
Sputum neutrophils (%)§ 44.8 (19.3-73.0) 49.3 (22.0-71.3) 61.5 (17.0-88.5) .21
Sputum eosinophils (%)§ 0.5 (0-2.3) 1.9 (0.3-6.3) 1.0 (0.3-2.5) .08
Pre-BD FEV1 (% predicted) 82.3 (24.4) 77.6 (23.3) 52.2 (21.7) 5E-10*
2E-11
.77
Post-BD FEV1 (% predicted) 89.2 (21.9) 82.7 (23.5) 57.8 (24.0) 1E-10*
4E-11
.38
Pre-BD FEV1/FVC ratio (%) 72.7 (9.8) 67.0 (12.0) 50.3 (12.5) 4E-18*
3E-17
.28
Post-BD FEV1/FVC ratio (%) 76.1 (9.6) 68.5 (11.4) 52.2 (12.7) 4E-21*
2E-17
.001
BD response 0.19 (0.24) 0.16 (0.21) 0.18 (0.23) .79
KCO (% predicted) 107 (18.5) 101 (20.3) 79.7 (29.6) 2E-6*
1E-7
.82
RV/TLC (%) 37.7 (12) 41.2 (11) 32.7 (12) 3E-8*
2E-8
.40
Mean LA/BSA (mm2/m2) 10.7 (2.94) 11.4 (2.46) 11.0 (3.05) .29
Mean TA/BSA (mm2/m2) 27.9 (6.19) 29.6 (5.13) 28.5 (6.16) .19
Mean WA/BSA (mm2/m2) 17.2 (3.32) 18.2 (2.78) 17.4 (3.20) .12
Mean %WA 62.7 (2.21) 62.2 (2.05) 62.6 (2.36) .3
MLDE/I 0.866 (0.056) 0.856 (0.061) 0.910 (0.058) 5E-4*
1E-8
1.00
RVC 212.93 (11.34) 223.96 (10.47) 230.59 (12.22) 4E-16*
9E-20
.71
Insp VI2950 4.6 (2.0) 13.0 (3.2) 26.6 (6.13) 1E-72*
6E-57
1E-22
Exp VI2856 13.3 (8.3) 21.7 (12.6) 45.8 (18.8) 1E-22*
5E-20
.004
CTLVE/I 0.65 (0.09) 0.58 (0.11) 0.66 (0.13) 1.00*
4E-5
.004
(Continued)
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TABLE E7. (Continued)
Cluster 1: asthmatic patients,
n 5 42; patients with
COPD, n 5 2
Cluster 2: asthmatic patients,
n 5 94; patients with
COPD, n 5 24
Cluster 3: asthmatic patients,
n 5 25; patients with
COPD, n 5 47
Significance
(P value)
Perc15 (HU) 2905 (14.7) 2943 (8.7) 2972 (11.1) 5E-86*
1E-43
1E-51
LAC-D2950 21.92 (0.20) 21.84 (0.12) 21.80 (0.13) .22
Pi10 (mm2) 14.9 (1.28) 15.0 (1.41) 14.8 (1.28) .73
Po20 %WA 56.2 (2.37) 56.0 (2.34) 56.0 (2.83) .88
%WA (no. [%])§# 6 (14.3) 15 (12.7) 11 (15.3) .88
MLDE/I (no. [%])§# 2 (4.8) 8 (6.8) 20 (27.8) 8E-5
Perc15 (no. [%])k 0 (0) 0 (0) 31 (43.1) 6E-19
BD, Bronchodilator; BMI, body mass index; CTLVE/I, computed tomographic lung volume expiratory/inspiratory ratio; Exp VI2856, expiratory voxel index less than 2856 HU;
FVC, forced vital capacity; Insp VI2950, inspiratory voxel index less than 2950 HU; Pi10, wall area of theoretical airway with an internal perimeter of 10 mm; Po20 %WA,
percentage wall area of a theoretical airway with an external perimeter of 20 mm; RVC, relative voxel change; RV/TLC, residual volume/total lung capacity.
Intergroup comparison, parametric (nonparametric) data: The P value for 1-way ANOVA (Kruskal-Wallis test) has been presented unless the ANOVA (Kruskal-Wallis test) result
was significant (P < .05), in which case the P value has been presented for the Tukey (Dunn) test pairwise comparisons: *asthmatic patients versus patients with COPD, asthmatic
patients versus healthy subjects, and patients with COPD versus healthy subjects. Differences in proportions were tested by using the x2 test. Data are expressed as means (SDs),
§medians (interquartile ranges), or §proportions. #Greater than 2 SDs of healthy control subjects. kLess than 2 SDs of healthy control subjects.
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